Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Liabilities (2016 - 2025)

Editas Medicine (EDIT) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • Quarterly Other Non-Current Liabilities rose 42.88% to $4.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Sep 2025, up 42.88% year-over-year, with the annual reading at $3.1 million for FY2024, 70.67% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $4.7 million at Editas Medicine, up from $4.6 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $6.4 million in Q1 2025, with the low at $1.8 million in Q4 2023.
  • Average Other Non-Current Liabilities over 3 years is $3.9 million, with a median of $3.6 million recorded in 2024.
  • Peak annual rise in Other Non-Current Liabilities hit 83.21% in 2025, while the deepest fall reached 21.87% in 2025.
  • Over 3 years, Other Non-Current Liabilities stood at $1.8 million in 2023, then surged by 70.67% to $3.1 million in 2024, then surged by 52.6% to $4.7 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $4.7 million, $4.6 million, and $6.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.